Perseus Proteomics (4882) · FactRestated
Expiry of the PPMX-T001 Agreement and Removal from the Pipeline
First written in FY2022. 1 of 2 entries say "Restated". Latest entry: FY2023.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Pipeline removal due to the expiration of patents and the agreement covering PPMX-T001A theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2023RestatedAnnual report
「The patent for PPMX-T001 expired in June 2022, and the agreement with Chugai Pharmaceutical Co., Ltd. also expired. Accordingly, the program was removed from the pipeline.」
The company has reconfirmed that PPMX-T001 was removed from its pipeline following expiration of the patent term and the agreement. - FY2022First statedAnnual report
「PPMX-T001 has been removed from our pipeline because the patent covered by the agreement with Chugai Pharmaceutical Co., Ltd. expired on 21 June 2022, but development continues at Chugai Pharmaceutical Co., Ltd.」
The company removed PPMX-T001 from its pipeline following expiration of the patent covered by the agreement, while development of GC33 and ERY974 continues at Chugai Pharmaceutical.